Menu
← Oncology Approval Tracker
FDA DECISION ·
Iclusig
ponatinib · Takeda Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia; use in combination with chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The label moved ponatinib into initial treatment, with molecular residual disease response supporting accelerated approval.
What research teams should watch
Set up consistent molecular sampling and track cardiovascular assessment and any response-guided dosing changes.
PRIMARY RECORDS